Time Machine

Medical Scientists, Except Epidemiologists

Scrub through 138 years of this role's history — from when it first emerged, through every wave of technology that reshaped it, to the cited projections for where it's heading next.

Compound microscope + bacterial culture (Koch's postulates era)

Ultracentrifuge + electron microscope + radioisotope tracers

Recombinant DNA + monoclonal antibodies + PCR

Molecular biology — DNA double helix + Watson-Crick base pairing

Human Genome Project → next-generation sequencing

mRNA platform + AI-accelerated drug discovery + LLM research tools

19001925195019752000now

Drag the dot, click anywhere on the track, or use ← → arrow keys (Shift for 10-year jumps, PgUp/PgDn for 25).

2026

Known today as Medical Scientist, Except Epidemiologist (BLS SOC 19-1042)

US Employment

165K

BLS National Employment Matrix 2024 baseline for SOC 19-1042, as reported in the 2024-2034 projections cycle. Sector breakdown: Professional, Scientific, and Technical Services 60,500 (36.6%); Health Care and Social Assistance 54,900 (33.2%); Educational Services 31,200 (18.9%). The largest single category — research services and pharmaceutical/biotech R&D — exceeds academia, a shift from the pre-2000 profile when universities and the NIH dominated.

Median Annual Wage

$100,590

Source: BLS-OEWS

Tool of the era · mRNA platform + AI-accelerated drug discovery + LLM research tools

Three overlapping technological platforms reshaped what a medical scientist does in the 2020s. First: the mRNA platform validated at scale by COVID vaccines. Katalin Karikó and Drew Weissman's 2005 discovery that chemically modified nucleoside bases could suppress the immune response to synthetic mRNA — work for which they received the 2023 Nobel Prize in Medicine — had languished for a decade before Moderna and BioNTech used it to design vaccine candidates within 48 hours of the SARS-CoV-2 sequence being published (January 11, 2020). The Moderna vaccine received FDA Emergency Use Authorization on December 18, 2020; BioNTech-Pfizer on December 11, 2020 — each under a year from sequence to authorization, shattering the previous record. Over 13 billion COVID-19 doses were administered globally. The platform is now in clinical trials for cancer, influenza, HIV, and RSV vaccines. Second: AI-accelerated drug discovery (Recursion, Insitro, Schrödinger) applies machine learning to high-content screening, ADMET prediction, and hit-to-lead optimization — compressing steps that previously took 3-5 years into months. Third: LLM-based research tools (Elicit, Consensus, Scite, Semantic Scholar) are reshaping the literature-review and hypothesis-generation phases of the job. A medical scientist can now run a structured systematic literature review in hours that previously took months.

The mRNA validation created a commercial-scale platform requiring an entirely new workforce: mRNA design scientists, lipid nanoparticle formulation chemists, and process development researchers. Moderna grew from ~800 employees (2019) to over 5,000 (2022). BioNTech grew from ~1,300 to over 4,500 in the same period. LLM tools are restructuring time allocation within the role but have not reduced headcount — they have shifted time from rote literature processing toward hypothesis testing and experimental design.

Projection cone · present → 2034

What credible sources project

Scrub the slider past now to anchor each scenario on the scrubber. The spread you see below is the range of futures credible sources project for this role.

WEF Future of Jobs Report 2025

→ 2030

+12%

WEF surveys across 1,000+ employers covering 14 million workers globally. Life and biological scientists — the category that encompasses Medical Scientists — are listed among the fastest-growing roles through 2030. The +12% approximation represents the WEF's biomedical research growth signal; the primary drivers are AI-enabled drug discovery (increasing research productivity and thus demand for scientists to run more experiments), aging population demographics across all OECD countries, and sustained public-sector investment in pandemic preparedness and cancer research. The WEF explicitly models AI as complementary to biomedical researchers rather than substitutive in the near term.

O*NET / BLS Occupational Outlook Handbook 2024

→ 2034

+11%

O*NET synthesizes the BLS OOH 2024-34 projections with the occupational classification. The OOH page (which returned HTTP 403 in this curation pass) is reported by O*NET as projecting "much faster than average" growth at approximately 11% — a commonly cited figure in secondary sources describing the 2024-34 cycle for this occupation. The 11% and 8.7% figures reflect different rounding or vintage of the same BLS data; both are directionally consistent. Annual openings of ~9,600 include new positions plus replacement need from retirements.

BLS National Employment Matrix 2024-34

→ 2034

+8.7%

BLS Employment Projections 2024-34 cycle. Baseline employment 165,300 (2024); projected 179,600 (2034); absolute change +14,300 positions. Annual job openings: approximately 9,600 per year. BLS describes the growth as "much faster than average" (defined as 7% or higher). Primary demand drivers: aging population increasing the burden of chronic disease requiring research-backed treatment; biopharmaceutical R&D expansion in mRNA therapeutics, gene therapy, and oncology immunotherapy; federal biomedical research infrastructure maintained at approximately $48B/year NIH budget. The matrix does not explicitly model AI-driven productivity effects.

Frey & Osborne (2013)

→ 2033

-5%

Gaussian-process classifier on O*NET task features. F&O assigned Medical Scientists a probability of computerization of approximately 0.054 — placing them in the lowest decile of their 702-occupation dataset. The bottleneck factors: high scores on "originality" (generating novel ideas), "scientific knowledge," and "complex problem solving." The -5% figure here is a theoretical lower bound representing the ceiling of the F&O scenario if realized at full strength; actual employment has grown substantially since 2013. F&O explicitly note that occupations requiring "original, creative, and judgment-intensive thinking" are poor candidates for computerization under their 2013 assumptions.

Eloundou et al. — "GPTs are GPTs" (2023)

→ 2028

-8%

GPT-4 task-by-task LLM exposure labeling on O*NET tasks for life/medical science occupations. Medical Scientists score high on LLM exposure for tasks classified as "information synthesis and writing" — literature review, grant writing, research protocol documentation, regulatory submission writing — but low for core experimental tasks (designing assays, operating instruments, analyzing data from novel experiments requiring judgment). The -8% figure represents the curator-estimated β (exposure with LLM tools) for the writing-and-synthesis component of the role, not total employment displacement. Eloundou et al. explicitly distinguish exposure from displacement; high exposure enables augmentation (faster literature review, better-drafted grants) rather than replacement. The overall β for the full task bundle is moderate; the γ (any exposure) is high because most scientists write.

Today, in this role

What's shifting in the work right now

The historical view above shows how this role has moved. This is the present-day detail: which AI tools are picking up which tasks, where the edge still is, and the natural directions this work can grow.

What's changing in your day

Three parts of your work where AI is already doing real lifting — and what stays yours.

AI is sitting alongside you here

Predict and analyze protein structures for drug target characterization — using AlphaFold 3 (DeepMind AlphaFold Server or local deployment) to predict three-dimensional structures of disease-relevant proteins and their co-complexes with small molecules, DNA, or RNA; interpreting binding pocket geometry, allosteric site accessibility, and conformational flexibility from predicted structures; validating high-confidence predictions against experimental data from PDB before using structural models to guide medicinal chemistry hypotheses.^[3],[6],[10]

Tools picking this up

AlphaFold 3 (DeepMind / Google) ↗NVIDIA BioNeMo ↗

Where your edge is

AlphaFold 3 is a genuine paradigm shift — predicting structures that previously required months of crystallography or cryo-EM time in under a day. Use it to pre-screen binding site hypotheses before committing to physical structural work, and build fluency with its confidence metrics (pLDDT scores, PAE matrices) so you can identify which predicted regions are reliable enough for medicinal chemistry guidance versus which require experimental validation. The structural biologist who knows how to critically interpret AI-predicted structures — not just run the server — is far more productive than one who either ignores these tools or trusts outputs uncritically.

AI is sitting alongside you here

Screen small molecule compound libraries against drug targets using AI-accelerated virtual screening — using Atomwise AtomNet or Schrödinger FEP+ to screen billions of virtual compounds for binding affinity and selectivity against a disease target; applying ADMET (absorption, distribution, metabolism, excretion, toxicity) filters to prioritize compounds with favorable pharmacological properties; selecting a tractable hit list for physical synthesis and biochemical validation; and interpreting false-positive risks given known target family off-target profiles.^{[13],[14],[10]}

Tools picking this up

Schrödinger AI Molecular Simulation ↗NVIDIA BioNeMo ↗

Where your edge is

Atomwise and Schrödinger AI can screen billions of compounds in weeks that would require years of physical HTS campaigns — adopt in silico primary screening before committing to physical library synthesis. Your scientific value is concentrated in the interpretation layer: deciding which predicted hits are likely true positives based on target biology (known binding modes, cofactor requirements, allosteric mechanisms), and which ADMET predictions to trust versus challenge with experimental PK/PD data. Build deep knowledge of your target family's structural pharmacology so you can identify when the scoring function is likely to fail (flexible binding sites, covalent mechanisms, allosteric targets) and design the validation tier accordingly.

AI is sitting alongside you here

Identify clinical trial cohorts and analyze real-world patient data for translational research — using Tempus AI's TIME (Trial Identification and Matching Engine) to query de-identified genomic and clinical data networks to identify patients meeting complex trial inclusion/exclusion criteria; analyzing genomic profiles alongside clinical outcomes data to identify biomarkers of drug response; and interpreting AI-flagged patient clusters in the context of known disease biology before making enrollment or analysis recommendations.^{[15],[16],[1]}

Tools picking this up

Tempus AI ↗

Where your edge is

Tempus AI can compress patient identification for clinical trials from months to weeks, but the translational scientist must verify that AI-identified patients genuinely meet protocol eligibility criteria — particularly complex exclusions based on prior treatment history or comorbidities that are captured inconsistently in structured data. Build a systematic eligibility verification workflow that includes clinical chart review for a randomly sampled validation set before treating AI-identified cohorts as enrollment-ready. The biomarker interpretation step — deciding which genomic co-cluster is mechanistically meaningful versus a statistical artifact — requires disease-specific biological knowledge that Tempus cannot provide.

Where this role is heading

Natural next steps for someone with your foundation — not exits, evolutions.

A direction you could grow

Natural Sciences Managers

Medical scientists who develop program management, team leadership, and cross-functional coordination skills — managing research teams, directing preclinical-to-clinical evidence development, and negotiating industry partnerships — transition naturally into Natural Sciences Manager roles at pharmaceutical companies, biotech organizations, or academic research centers. This path is especially timely as pharma organizations navigate the rapid expansion of AI drug discovery tooling: deciding which AI platforms to adopt, setting review standards for AI-generated molecular candidates, and managing teams of computational biologists alongside wet-lab researchers requires scientific leaders with both research credibility and operational scope. Natural Sciences Managers at pharma and biotech companies earn median $162,760 (BLS 2024), and BLS projects +7% growth through 2034. The PI track record — grant management, publication leadership, trainee mentorship, and vendor/CRO relationships — maps directly to the management skills required.

What you'd add

· Research program management: portfolio prioritization across multiple research threads, CRO and vendor governance, milestone-based go/no-go decision frameworks for preclinical drug candidates
· AI tool strategy and governance in R&D: evaluating AI drug discovery platforms (BenchSci, Cradle, Recursion), setting organizational standards for AI-generated scientific claims, and managing compute budgets for ML workloads
· Industry regulatory literacy: IND application process, FDA pre-IND meeting strategy, CMC (Chemistry, Manufacturing, and Controls) program oversight for biologics and small molecules
· People management in science: hiring scientists, conducting performance reviews, career development coaching in academic vs. industry contexts, managing interdisciplinary team dynamics
· Business development skills: licensing deal structures for research collaborations, SBIR/STTR grant management, NIH cooperative agreement and pharma sponsored-research agreement (SRA) structures

What it takesSome new skills to pick up

Present-day sources

Sources

Every claim on this page traces back to one of the following. Updated 2026-05-23.

Share this year

Drops anyone you send it to straight into 2026.

Preview card

Different role?

See the same long-arc view for your own profession.

Browse the directory by industry, or search by title or SOC code. New roles ship every few weeks — every profile cites every claim.

Browse all roles